[go: up one dir, main page]

RU2017115719A3 - - Google Patents

Download PDF

Info

Publication number
RU2017115719A3
RU2017115719A3 RU2017115719A RU2017115719A RU2017115719A3 RU 2017115719 A3 RU2017115719 A3 RU 2017115719A3 RU 2017115719 A RU2017115719 A RU 2017115719A RU 2017115719 A RU2017115719 A RU 2017115719A RU 2017115719 A3 RU2017115719 A3 RU 2017115719A3
Authority
RU
Russia
Application number
RU2017115719A
Other versions
RU2684911C2 (ru
RU2017115719A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2017115719A3 publication Critical patent/RU2017115719A3/ru
Publication of RU2017115719A publication Critical patent/RU2017115719A/ru
Application granted granted Critical
Publication of RU2684911C2 publication Critical patent/RU2684911C2/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/10Cellular immunotherapy characterised by the cell type used
    • A61K40/19Dendritic cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/20Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24Antigen-presenting cells [APC]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/40Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41Vertebrate antigens
    • A61K40/42Cancer antigens
    • A61K40/4262Heat shock proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/53Liver

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
RU2017115719A 2014-10-07 2015-10-07 Пептид, полученный из hsp70, фармацевтическая композиция для лечения или профилактики рака, содержащая такой пептид, индуктор иммунного ответа и способ получения антиген-презентирующей клетки RU2684911C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2014-206730 2014-10-07
JP2014206730 2014-10-07
PCT/JP2015/078504 WO2016056596A1 (ja) 2014-10-07 2015-10-07 Hsp70由来のペプチド、これを用いた癌の治療又は予防のための医薬組成物、免疫誘導剤、及び抗原提示細胞の製造方法

Publications (3)

Publication Number Publication Date
RU2017115719A3 true RU2017115719A3 (ru) 2018-11-14
RU2017115719A RU2017115719A (ru) 2018-11-14
RU2684911C2 RU2684911C2 (ru) 2019-04-16

Family

ID=55653202

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017115719A RU2684911C2 (ru) 2014-10-07 2015-10-07 Пептид, полученный из hsp70, фармацевтическая композиция для лечения или профилактики рака, содержащая такой пептид, индуктор иммунного ответа и способ получения антиген-презентирующей клетки

Country Status (12)

Country Link
US (3) US10537626B2 (ru)
EP (2) EP3205661B1 (ru)
JP (1) JP6423889B2 (ru)
CN (1) CN107001418A (ru)
AU (2) AU2015329070B2 (ru)
BR (1) BR112017006969A2 (ru)
CA (2) CA3116265A1 (ru)
DK (1) DK3205661T3 (ru)
ES (1) ES2882827T3 (ru)
RU (1) RU2684911C2 (ru)
TW (1) TWI687434B (ru)
WO (1) WO2016056596A1 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015329070B2 (en) 2014-10-07 2018-11-22 Nec Corporation Hsp70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen-presenting cell
DK3269733T3 (da) 2015-03-09 2020-07-27 Cytlimic Inc Peptid afledt af gpc3, farmaceutisk sammensætning til behandling eller forebyggelse af cancer under anvendelse deraf, immunitetsinducer og fremgangsmåde til fremstilling af antigenpræsenterende celler
CN107530432B (zh) 2015-04-07 2021-04-27 Cytlimic公司 药物
RU2759728C2 (ru) * 2016-10-11 2021-11-17 Ситлимик Инк. Лекарственное средство
US20250236642A1 (en) * 2022-02-25 2025-07-24 Nec Corporation Pharmaceutical composition for treatment or prevention of adult t-cell leukemia

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196523A (en) * 1985-01-01 1993-03-23 The University Of Southern California Control of gene expression by glucose, calcium and temperature
JPH08151396A (ja) * 1994-11-28 1996-06-11 Teijin Ltd Hla結合性オリゴペプチド及びそれを含有する免疫調節剤
RS50101B (sr) 1996-02-24 2009-01-22 Boehringer Ingelheim International Gmbh., Farmaceutski preparati za imunomodulaciju
EP0893507A1 (en) 1997-07-25 1999-01-27 Institut Gustave Roussy Use of MHC class II ligands (CD4 and LAG-3) as adjuvant for vaccination and of LAG-3 in cancer treatment
EP1303287A4 (en) * 2000-06-16 2006-02-08 Argonex Pharmaceuticals MHC PEPTIDES OVEREXPRESSED IN PROSTATE CANCER CELL AND METHODS FOR THEIR USE
US7517948B2 (en) * 2000-09-13 2009-04-14 Multimmune Gmbh Hsp70 peptide stimulating natural killer (NK) cell activity and uses thereof
CN1555272A (zh) * 2001-07-31 2004-12-15 �ո��� 调节免疫应答的组合物和方法
WO2004018667A1 (ja) 2002-08-26 2004-03-04 Kirin Beer Kabushiki Kaisha ペプチド及びこれを含む医薬
EP2572715A1 (en) 2002-12-30 2013-03-27 3M Innovative Properties Company Immunostimulatory Combinations
FR2863890B1 (fr) 2003-12-19 2006-03-24 Aventis Pasteur Composition immunostimulante
WO2006004182A1 (ja) 2004-07-07 2006-01-12 Nec Corporation 配列予測システム
MX2007014390A (es) 2005-05-19 2008-02-12 Glaxosmithkline Biolog Sa Composicion de vacuna que comprende subunidad b de termo toxina e. coli y antigeno y adyuvante.
WO2007018199A1 (ja) 2005-08-09 2007-02-15 Kumamoto University HLA-A2陽性者用glypican-3(GPC3)由来癌拒絶抗原ペプチド及びこれを含む医薬
WO2007119515A1 (ja) * 2006-03-28 2007-10-25 Dainippon Sumitomo Pharma Co., Ltd. 新規腫瘍抗原ペプチド
RU2333767C2 (ru) 2006-03-31 2008-09-20 Автономная некоммерческая организация "Институт молекулярной диагностики" (АНО "ИнМоДи") Вакцинные композиции, способы их применения для профилактики и лечения меланомы и генетические конструкции для получения действующих компонентов композиции
CN101311270A (zh) 2006-08-18 2008-11-26 上海交通大学医学院 一种可诱生细胞免疫应答的真核表达载体及其疫苗
EP2695895A1 (en) 2006-10-17 2014-02-12 Oncotherapy Science, Inc. Peptide vaccines for cancers expressing MPHOSPH1 or DEPDC1 polypeptides
WO2008106491A2 (en) 2007-02-27 2008-09-04 University Of Utah Research Foundation Peptides that interact with topoisomerase i and methods thereof
EP2170361B1 (en) * 2007-07-06 2016-05-25 Universiteit Utrecht Holding B.V. Treatment and prevention of inflammatory diseases and autoimmune diseases
EP2195333A1 (en) 2007-09-12 2010-06-16 Anaphore, Inc. Hsp70-based treatment for autoimmune diseases
KR100900837B1 (ko) 2007-12-07 2009-06-04 (주)두비엘 리포펩타이드와 폴리(i:c)를 아쥬반트로 포함하는 강력한백신 조성물
WO2011017162A2 (en) * 2009-08-03 2011-02-10 The Johns Hopkins University Methods for enhancing antigen-specific immune responses
JP5796014B2 (ja) 2009-10-06 2015-10-21 パナセラ ラブス, インコーポレイテッド がんを処置するためのトール様受容体およびトール様受容体アゴニストの使用
WO2012139094A2 (en) 2011-04-08 2012-10-11 H. Lee Moffitt Cancer Center And Research Institute, Inc. Method of developing a vaccine using peptide-poly ic complexes
CA2863653A1 (en) 2012-02-02 2013-08-08 California Stem Cell, Inc. Pluripotent germ layer origin antigen presenting cancer vaccine
CN104203277A (zh) * 2012-02-07 2014-12-10 拉霍拉敏感及免疫学研究所 梯牧草变应原和用于调节免疫反应的方法和用途
US20130217122A1 (en) 2012-02-21 2013-08-22 The Trustees Of The University Of Pennsylvania Expansion of Interferon-Gamma-Producing T-Cells Using Glypican-3 Peptide Library
WO2013143026A1 (en) * 2012-03-31 2013-10-03 Abmart (Shanghai) Co., Ltd Peptide and antibody libraries and uses thereof
TWI693073B (zh) 2012-12-21 2020-05-11 日商中外製藥股份有限公司 對gpc3標的治療劑療法為有效之患者投與的gpc3標的治療劑
CN103897047B (zh) * 2012-12-27 2016-01-20 中国科学院植物研究所 蛋白BhHSP70-1及其编码基因与应用
EP2961388B1 (en) 2013-03-01 2019-04-24 Astex Pharmaceuticals, Inc. Drug combinations
EP3137105A4 (en) 2014-04-30 2017-12-27 President and Fellows of Harvard College Combination vaccine devices and methods of killing cancer cells
AU2015329070B2 (en) 2014-10-07 2018-11-22 Nec Corporation Hsp70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen-presenting cell
DK3269733T3 (da) 2015-03-09 2020-07-27 Cytlimic Inc Peptid afledt af gpc3, farmaceutisk sammensætning til behandling eller forebyggelse af cancer under anvendelse deraf, immunitetsinducer og fremgangsmåde til fremstilling af antigenpræsenterende celler
CN107530432B (zh) 2015-04-07 2021-04-27 Cytlimic公司 药物

Also Published As

Publication number Publication date
EP3205661A1 (en) 2017-08-16
US20220193213A1 (en) 2022-06-23
EP3205661A4 (en) 2018-08-08
TW201619190A (zh) 2016-06-01
EP3925968A3 (en) 2022-03-02
CA3116265A1 (en) 2016-04-14
AU2015329070A1 (en) 2017-04-27
US11304997B2 (en) 2022-04-19
AU2015329070B2 (en) 2018-11-22
BR112017006969A2 (pt) 2017-12-19
ES2882827T3 (es) 2021-12-02
RU2684911C2 (ru) 2019-04-16
US20180169199A1 (en) 2018-06-21
TWI687434B (zh) 2020-03-11
US10537626B2 (en) 2020-01-21
AU2018274976A1 (en) 2019-01-03
US20200121772A1 (en) 2020-04-23
EP3205661B1 (en) 2021-07-07
CN107001418A (zh) 2017-08-01
US12448413B2 (en) 2025-10-21
JP6423889B2 (ja) 2018-11-14
AU2018274976B2 (en) 2019-05-02
DK3205661T3 (da) 2021-08-02
CA2963909A1 (en) 2016-04-14
EP3925968A2 (en) 2021-12-22
CA2963909C (en) 2021-06-15
JPWO2016056596A1 (ja) 2017-08-17
WO2016056596A1 (ja) 2016-04-14
RU2017115719A (ru) 2018-11-14

Similar Documents

Publication Publication Date Title
BR112016018811A2 (ru)
BR112016016951A2 (ru)
BR112016018555A2 (ru)
BR112016016705A2 (ru)
BR112016016225A2 (ru)
BR112016016602A2 (ru)
BR112016016088A2 (ru)
BR112016016978A2 (ru)
BR112016016503A2 (ru)
BR112016016689A2 (ru)
BR112016018369A2 (ru)
BR112016016770A2 (ru)
BR112016016451A2 (ru)
BR112016016106A2 (ru)
BR112016017226A2 (ru)
BR112016016364A2 (ru)
BR112016018575A2 (ru)
BR112016018833A2 (ru)
BR112016015642A2 (ru)
BR112016018252A2 (ru)
BR112016016403A2 (ru)
BR112016016974A2 (ru)
BR112016016459A2 (ru)
BR112016015911A2 (ru)
BR112016021414A2 (ru)